Eli Lilly & Co. (LLY) Tops Q1 EPS by 10c; Raises guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
Go back to Eli Lilly & Co. (LLY) Tops Q1 EPS by 10c; Raises guidance
April 30, 2024 4:50 PM EDT
BMO Capital analyst Evan David Seigerman raised the price target on Eli Lilly (NYSE: LLY) to $1,001.00 (from $900.00) while maintaining a Outperform rating.
The analyst comments "A high-quality earnings miss is one that 1) characterizes unprecedented demand; 2) justifies performance miss with supply constraints; 3) highlights efforts... More
April 30, 2024 2:01 PM EDT
Cantor Fitzgerald analyst Louise Chen raised the price target on Eli Lilly (NYSE: LLY) to $885.00 (from $815.00) while maintaining a Overweight rating.
The analyst comments "For 1Q24, US Zepbound revenue was $517MM vs. $363MM for FactSet. Zepbound is already annualizing at over... More
April 30, 2024 6:59 AM EDT
(Updated - April 30, 2024 10:00 AM EDT)
Eli Lilly & Co. (NYSE: LLY) saw its shares jump over 7% at the open on Tuesday after the pharmaceutical giant reported better-than-expected earnings and gross margin for the fiscal Q1 2024.
Specifically, Eli Lilly posted earnings per share (EPS) of $2.58, beating the analyst expectations of $2.48. However, the company's revenue for the quarter was $8.77 billion, falling short of the consensus estimate of $8.94 billion.
Importantly, the company's gross margin improved significantly, reaching 80.9% compared to 76.6% in the same period last year... More
